

# Donna Neuberg

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8409797/donna-neuberg-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

325  
papers

27,045  
citations

73  
h-index

163  
g-index

341  
ext. papers

33,764  
ext. citations

9.2  
avg, IF

6.29  
L-index

#	Paper	IF	Citations
325	Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001.. <i>Pediatric Blood and Cancer</i> , <b>2022</b> , e29583		0
324	Landscape of helper and regulatory antitumour CD4 T cells in melanoma.. <i>Nature</i> , <b>2022</b> , 605, 532-538	50.4	2
323	Immune recall improves antibody durability and breadth to SARS-CoV-2 variants.. <i>Science Immunology</i> , <b>2022</b> , eabp8328	28	5
322	Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study. <i>PLoS Medicine</i> , <b>2022</b> , 19, e1004012	11.6	
321	Activation of Notch and Myc signaling via B cell-restricted depletion of Dnmt3a generates a consistent murine model of chronic lymphocytic leukemia. <i>Cancer Research</i> , <b>2021</b> ,	10.1	1
320	Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 176	7	3
319	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5049-5061	12.9	
318	Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. <i>Cell Reports</i> , <b>2021</b> , 37, 109992	10.6	3
317	High Incidence of Bleeding Found with Direct Oral Anticoagulant Use in Myeloproliferative Neoplasm Patients. <i>Blood</i> , <b>2021</b> , 138, 3632-3632	2.2	0
316	Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E259-E262	7.1	1
315	The clinical and functional effects of TERT variants in myelodysplastic syndrome. <i>Blood</i> , <b>2021</b> , 138, 898-911	11.1	4
314	Testing for clonal hematopoiesis of indeterminate potential in breast cancer survivors.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e24108-e24108	2.2	
313	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. <i>Cancer Discovery</i> , <b>2021</b> ,	24.4	5
312	is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicing. <i>Blood Cancer Discovery</i> , <b>2021</b> , 2, 500-517	7	0
311	Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3496-3505	2.2	10
310	Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. <i>Pediatric Blood and Cancer</i> , <b>2021</b> , 68, e28719	3	6
309	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. <i>Blood Cancer Discovery</i> , <b>2021</b> , 2, 54-69	7	6

308	Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. <i>Nature Medicine</i> , <b>2021</b> , 27, 515-525	50.5	69
307	Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. <i>Leukemia</i> , <b>2021</b> , 35, 2688-2692	10.7	2
306	A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. <i>Cancer Cell</i> , <b>2021</b> , 39, 380-393.e8	24.3	7
305	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5072-5083	12.9	3
304	Phenotype, specificity and avidity of antitumour CD8 T cells in melanoma. <i>Nature</i> , <b>2021</b> , 596, 119-125	50.4	53
303	Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment.. <i>Nature Cancer</i> , <b>2021</b> , 2, 758-772	15.4	8
302	Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2825-2834	15.4	2
301	Genomic Profiling of a Randomized Trial of Interferon- $\gamma$ versus Hydroxyurea in MPN Reveals Mutation-Specific Responses. <i>Blood Advances</i> , <b>2021</b> ,	7.8	3
300	Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. <i>Cell</i> , <b>2021</b> , 184, 4969-4980.e15	56.2	42
299	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. <i>Nature Communications</i> , <b>2021</b> , 12, 5395	17.4	1
298	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5049-5061	12.9	2
297	HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 541-547	2.6	7
296	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , <b>2020</b> , 136, 157-170	2.2	72
295	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , <b>2020</b> , 26, 909-918	50.5	155
294	Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. <i>Blood Advances</i> , <b>2020</b> , 4, 2254-2260	7.8	9
293	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , <b>2020</b> , 11, 2996	17.4	34
292	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2556-2564	12.9	32
291	Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 860-865	5.1	5

290	Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy. <i>Scientific Reports</i> , <b>2020</b> , 10, 723	4.9	13
289	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. <i>Haematologica</i> , <b>2020</b> , 105, 1361-1368	6.6	15
288	CIMAC-CIDC tissue imaging harmonization.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3125-3125	2.2	1
287	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5010-5010	2.2	2
286	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , <b>2020</b> , 7, e122-e133	14.6	11
285	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. <i>Nature Medicine</i> , <b>2020</b> , 26, 1468-1479	50.5	39
284	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , <b>2020</b> , 26, 1549-1556	50.5	118
283	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	7
282	Endogenous Glucocorticoid Signaling Regulates CD8 T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment. <i>Immunity</i> , <b>2020</b> , 53, 658-671.e6	32.3	35
281	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. <i>Blood</i> , <b>2020</b> , 136, 3070-3081	2.2	13
280	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. <i>Cancer Cell</i> , <b>2019</b> , 36, 369-384.e13	24.3	107
279	A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. <i>Cancer Cell</i> , <b>2019</b> , 35, 283-296.e5	24.3	37
278	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. <i>Nature</i> , <b>2019</b> , 570, 474-479	50.4	47
277	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. <i>Cancer Cell</i> , <b>2019</b> , 35, 664-676.e7	24.3	43
276	Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. <i>Blood</i> , <b>2019</b> , 133, 2651-2663	2.2	10
275	A dominant-negative effect drives selection of missense mutations in myeloid malignancies. <i>Science</i> , <b>2019</b> , 365, 599-604	33.3	127
274	Severe CD4+ T-cell lymphopenia is not observed in frequent plateletpheresis donors collected on the Fenwal Amicus. <i>Transfusion</i> , <b>2019</b> , 59, 2783-2787	2.9	4
273	Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease. <i>PLoS ONE</i> , <b>2019</b> , 14, e0218783	3.7	3

272	Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 1189-1197	2.6	5
271	Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	59
270	Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response. <i>Blood</i> , <b>2019</b> , 134, 4202-4202	2.2	1
269	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , <b>2019</b> , 134, 4172-4172	2.2	4
268	Interrogation of Individual CLL Loss-of-Function Lesions By CRISPR In Vivo Editing Reveals Common and Unique Pathway Alterations. <i>Blood</i> , <b>2019</b> , 134, 684-684	2.2	2
267	A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2019</b> , 134, 3867-3867	2.2	13
266	Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 10006-10006	2.2	5
265	B Cell Restricted Expression of Mutated IKZF3 modulates BCR Signaling and Homing Pathways in a Mouse Model of CLL. <i>Blood</i> , <b>2019</b> , 134, 848-848	2.2	
264	T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation. <i>Blood</i> , <b>2019</b> , 134, 680-680	2.2	0
263	Lineage Tracing in Chronic Lymphocytic Leukemia Reveals Clones with Stable Gene Expression States That Differentially Respond to Therapy. <i>Blood</i> , <b>2019</b> , 134, 1229-1229	2.2	
262	Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL. <i>Blood</i> , <b>2019</b> , 134, 4281-4281	2.2	
261	MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers. <i>Blood</i> , <b>2019</b> , 134, 1284-1284	2.2	0
260	Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL). <i>Blood</i> , <b>2019</b> , 134, 516-516	2.2	
259	Inducible Phase Separation of GSK3 $\beta$ As a Mechanism for Asparaginase Resistance in Acute Leukemias. <i>Blood</i> , <b>2019</b> , 134, 169-169	2.2	
258	Recurrent Intracranial Hemorrhage and Venous Thromboembolism Following Initial Intracranial Hemorrhage in Patients with Brain Tumors on Anticoagulation. <i>Blood</i> , <b>2019</b> , 134, 2438-2438	2.2	
257	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-None Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. <i>Blood</i> , <b>2019</b> , 134, 2015-2015	2.2	0
256	Deciphering the Role of Locally Disordered DNA Methylation on CLL Development In Vivo. <i>Blood</i> , <b>2019</b> , 134, 1737-1737	2.2	
255	Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies. <i>Blood</i> , <b>2019</b> , 134, 2549-2549	2.2	

254	A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503. <i>Blood</i> , <b>2019</b> , 134, 4592-4592	2.2	
253	CD4+ T-cell lymphopenia in frequent platelet donors who have ceased platelet donation for at least 1 year. <i>Transfusion</i> , <b>2019</b> , 59, 1644-1647	2.9	5
252	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. <i>Nature</i> , <b>2019</b> , 565, 234-239	50.4	569
251	Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 100-112	12.5	128
250	Plateletpheresis-associated lymphopenia in frequent platelet donors. <i>Blood</i> , <b>2019</b> , 133, 605-614	2.2	8
249	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 446-454	7.1	28
248	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. <i>Leukemia</i> , <b>2019</b> , 33, 1747-1758	10.7	88
247	Postoperative bridging anticoagulation and left ventricular assist system thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 47, 57-66	5.1	2
246	Influence of BCL2L1 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 33-41	3.5	11
245	PPAR $\gamma$ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 723-732	12.5	14
244	Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. <i>Blood</i> , <b>2018</b> , 132, 170-178	2.2	28
243	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , <b>2018</b> , 32, 2126-2137	10.7	38
242	Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e27062	3	31
241	Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	165
240	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. <i>Cell</i> , <b>2018</b> , 173, 624-633.e8	56.2	71
239	The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 306-314	5.1	25
238	Association of mutations with morphological dysplasia in acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. <i>Haematologica</i> , <b>2018</b> , 103, 626-633	6.6	12
237	Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e26952	3	20

236	Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e27082	3	
235	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , <b>2018</b> , 24, 679-690	50.5	659
234	Microbial symbionts regulate the primary Ig repertoire. <i>Journal of Experimental Medicine</i> , <b>2018</b> , 215, 1397-1415	34	
233	Autochthonous tumors driven by loss have an ongoing requirement for the RBP2 histone demethylase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E3741-E3748	11.5	6
232	Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 597-600	4.5	3
231	Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. <i>Cancer</i> , <b>2018</b> , 124, 306-314	6.4	17
230	A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. <i>Blood</i> , <b>2018</b> , 132, 1911-1921	2.2	31
229	Mass cytometry of Hodgkin lymphoma reveals a CD4 regulatory T-cell-rich and exhausted T-effector microenvironment. <i>Blood</i> , <b>2018</b> , 132, 825-836	2.2	85
228	Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e27256	3	18
227	CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. <i>Cancer Discovery</i> , <b>2018</b> , 8, 884-897	24.4	42
226	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	21
225	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. <i>Blood</i> , <b>2018</b> , 132, 228-228	2.2	11
224	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , <b>2018</b> , 132, 749-749	2.2	6
223	Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 766-766	2.2	7
222	A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 1654-1654	2.2	2
221	Telomere Length and Telomerase Complex Mutations Predict Fatal Treatment Toxicity after Stem Cell Transplantation in Patients with Myelodysplastic Syndrome. <i>Blood</i> , <b>2018</b> , 132, 796-796	2.2	3
220	Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies. <i>Blood</i> , <b>2018</b> , 132, 893-893	2.2	3
219	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. <i>Blood</i> , <b>2018</b> , 132, 891-891	2.2	

218	Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults. <i>Blood</i> , <b>2018</b> , 132, 2704-2704	2.2	
217	Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study). <i>Blood</i> , <b>2018</b> , 132, 985-985	2.2	
216	Sudden Death in Sickle Cell Disease: An Assessment of Risk Factors. <i>Blood</i> , <b>2018</b> , 132, 4929-4929	2.2	
215	Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults. <i>Blood</i> , <b>2018</b> , 132, 4059-4059	2.2	
214	Single Cell Transcriptomic Characterization of the Immune Microenvironment in Naturally Progressing Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2018</b> , 132, 3112-3112	2.2	
213	CD4+ T-Cell Lymphopenia in Frequent Platelet Donors Who Have Ceased Platelet Donation for at Least 1 Year. <i>Blood</i> , <b>2018</b> , 132, 2550-2550	2.2	
212	Safety of Direct-Acting Oral Anticoagulants Versus Enoxaparin in Patients with Primary and Metastatic Brain Tumors. <i>Blood</i> , <b>2018</b> , 132, 2521-2521	2.2	
211	KZF-L162R Mutation Affects Splenic Mature B Cell Development and Alters Expression of Aiolos Target Genes. <i>Blood</i> , <b>2018</b> , 132, 668-668	2.2	
210	Mapping the Evolution of T Cell Transcriptional States during DLI Response and Resistance Using Single-Cell Data. <i>Blood</i> , <b>2018</b> , 132, 821-821	2.2	
209	Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2018</b> , 132, 820-820	2.2	
208	Potential Barriers to Clinical Trials of New Therapeutics for Myelodysplastic Syndromes: Wide Variation in Risk Definitions and Trial Enrollment Criteria. <i>Blood</i> , <b>2018</b> , 132, 4378-4378	2.2	
207	Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 1431-1431	2.2	
206	PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL. <i>Blood</i> , <b>2018</b> , 132, 889-889	2.2	
205	An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e26871	3	10
204	Wrangling with P-values. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e26834	3	
203	Reply to Z. Wu et al. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2657	2.2	
202	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 942-950	2.2	175
201	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , <b>2018</b> , 215, 3094-3114	16.6	26



200	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. <i>Blood Advances</i> , <b>2018</b> , 2, 529-533	7.8	21
199	Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. <i>Blood Advances</i> , <b>2018</b> , 2, 1449-1458	7.8	44
198	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , <b>2018</b> , 215, 1929-1945	16.6	11
197	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1598-1605	2.2	208
196	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 536-547	59.2	383
195	Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. <i>Blood</i> , <b>2017</b> , 129, 3379-3385	2.2	46
194	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4680-4692	12.9	4
193	Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 111-121	59.2	991
192	NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. <i>American Journal of Hematology</i> , <b>2017</b> , 92, E123-E124	7.1	8
191	Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. <i>Haematologica</i> , <b>2017</b> , 102, 498-508	6.6	28
190	Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. <i>Haematologica</i> , <b>2017</b> , 102, 719-727	6.6	26
189	How many mice? Design considerations for murine studies. <i>Blood Advances</i> , <b>2017</b> , 1, 1466	7.8	1
188	LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. <i>Cancer Cell</i> , <b>2017</b> , 32, 310-323.e5	24.3	52
187	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. <i>Blood</i> , <b>2017</b> , 130, 2420-2430	2.2	174
186	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 8614-8619	11.5	25
185	Analysis of persistence and antibiotic response in colorectal cancer. <i>Science</i> , <b>2017</b> , 358, 1443-1448	33.3	578
184	An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> , <b>2017</b> , 547, 217-221	50.4	1375
183	Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. <i>Genome Research</i> , <b>2017</b> , 27, 1300-1311	9.7	50

182	The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. <i>Nature Communications</i> , <b>2017</b> , 8, 2185	17.4	99
181	Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. <i>Oncotarget</i> , <b>2017</b> , 8, 67639-67650	3.3	20
180	Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. <i>Blood Advances</i> , <b>2017</b> , 1, 1645-1649	7.8	28
179	Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. <i>JCI Insight</i> , <b>2017</b> , 2, e89373	9.9	65
178	Amino acid-insensitive mTORC1 regulation enables nutritional stress resilience in hematopoietic stem cells. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 1405-1413	15.9	15
177	Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. <i>Oncotarget</i> , <b>2017</b> , 8, 43752-43767	3.3	27
176	Fetal Erythropoiesis Is Defective in Rpl11 Heterozygous Mice and Increases in Severity in Young Animals. <i>Blood</i> , <b>2017</b> , 130, 872-872	2.2	
175	Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. <i>Blood Advances</i> , <b>2016</b> , 1, 84-92	7.8	6
174	Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices. <i>Nature Chemical Biology</i> , <b>2016</b> , 12, 845-52	11.7	131
173	Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E7701-E7709	11.5	71
172	Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBP $\beta$ expression. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 350ra104	17.5	37
171	Classical Hodgkin Lymphoma with Reduced $\alpha$ M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 910-916	12.5	118
170	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , <b>2016</b> , 7, 11589	17.4	220
169	Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , <b>2016</b> , 30, 750-763	24.3	115
168	Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010). <i>Pediatric Blood and Cancer</i> , <b>2016</b> , 63, 1012-8	3	54
167	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. <i>Nature Medicine</i> , <b>2016</b> , 22, 792-9	50.5	217
166	MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice. <i>American Journal of Clinical Pathology</i> , <b>2016</b> , 145, 166-79	1.9	22
165	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. <i>JAMA Oncology</i> , <b>2016</b> , 2, 518-22	13.4	95

164	Intracranial Hemorrhage in Patients with Primary Brain Tumors Treated with Therapeutic Enoxaparin: A Matched Cohort Study. <i>Blood</i> , <b>2016</b> , 128, 142-142	2.2	1
163	Randomized Study of Pegaspargase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001. <i>Blood</i> , <b>2016</b> , 128, 175-175	2.2	9
162	The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL. <i>Blood</i> , <b>2016</b> , 128, 188-188	2.2	3
161	Chromosome 9p24.1/PD-L1/PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). <i>Blood</i> , <b>2016</b> , 128, 2923-2923	2.2	4
160	Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 4052-4052	2.2	23
159	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 604-604	2.2	1
158	Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2016</b> , 128, 69-69	2.2	2
157	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 986-986	2.2	1
156	Post-Operative Anticoagulation and the Incidence of Left Ventricular Assist Device Thrombosis. <i>Blood</i> , <b>2016</b> , 128, 2620-2620	2.2	
155	A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia. <i>Blood</i> , <b>2016</b> , 128, 5218-5218	2.2	
154	The Impact of Regional Cardiovascular Care Outcomes on Survival and Cardiovascular-Specific Mortality in Myelodysplastic Syndrome. <i>Blood</i> , <b>2016</b> , 128, 5984-5984	2.2	
153	Progression in Patients with with Low- and Intermediate-1 Risk Del(5q) MDS Is Predicted By a Limited Subset of Mutations. <i>Blood</i> , <b>2016</b> , 128, 4329-4329	2.2	
152	Genome-Wide Analysis of a Novel Murine Model of Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 967-967	2.2	
151	Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001. <i>Blood</i> , <b>2016</b> , 128, 761-761	2.2	
150	PDI Inhibition Blocks Thrombin Generation in Humans By Interfering with Platelet Factor V Activation. <i>Blood</i> , <b>2016</b> , 128, 2628-2628	2.2	
149	Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium. <i>Blood</i> , <b>2016</b> , 128, 1729-1729	2.2	
148	Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. <i>Cancer</i> , <b>2016</b> , 122, 946-53	6.4	27
147	Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 322-9	7.1	54

146	Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 793-9	7.1	11
145	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , <b>2016</b> , 128, 2931-2940	2.2	75
144	Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 207-211	4.7	74
143	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2690-7	2.2	472
142	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , <b>2016</b> , 29, 574-586	24.3	154
141	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. <i>Blood</i> , <b>2016</b> , 128, 1093-100	2.2	78
140	Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. <i>Blood</i> , <b>2016</b> , 128, 1845-1853	2.2	58
139	The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. <i>British Journal of Haematology</i> , <b>2016</b> , 173, 105-13	4.5	50
138	Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. <i>Leukemia</i> , <b>2015</b> , 29, 1555-1563	10.7	34
137	Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2015</b> , 21, 632-8	3.3	9
136	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3178-86	12.9	23
135	Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1252-7	2.2	51
134	A strategy to improve treatment-related mortality and abandonment of therapy for childhood ALL in a developing country reveals the impact of treatment delays. <i>Pediatric Blood and Cancer</i> , <b>2015</b> , 62, 1395-402	3	28
133	Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 1677-90	21.7	145
132	Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 3336-42	1.9	29
131	Mutations driving CLL and their evolution in progression and relapse. <i>Nature</i> , <b>2015</b> , 526, 525-30	50.4	658
130	Sequence-Intrinsic Mechanisms that Target AID Mutational Outcomes on Antibody Genes. <i>Cell</i> , <b>2015</b> , 163, 1124-1137	56.2	103
129	Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. <i>Journal of Molecular Diagnostics</i> , <b>2015</b> , 17, 19-30	5.1	19

128	Marked hyperferritinemia does not predict for HLH in the adult population. <i>Blood</i> , <b>2015</b> , 125, 1548-52	2.2	127
127	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. <i>Blood</i> , <b>2015</b> , 125, 1367-76	2.2	497
126	Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea. <i>Blood</i> , <b>2015</b> , 125, 3668-9	2.2	19
125	Mitochondrial Variations in Non-Small Cell Lung Cancer (NSCLC) Survival. <i>Cancer Informatics</i> , <b>2015</b> , 14, 1-9	2.4	10
124	Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 694-703	4.5	16
123	The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks. <i>Cancer Informatics</i> , <b>2015</b> , 14, 141-8	2.4	15
122	Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. <i>Blood</i> , <b>2015</b> , 126, 494-9	2.2	92
121	Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2205-11	2.2	51
120	Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. <i>Modern Pathology</i> , <b>2015</b> , 28, 965-76	9.8	20
119	Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E $\mu$ -TCL1 CLL mouse model. <i>Blood</i> , <b>2015</b> , 126, 212-21	2.2	82
118	Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 329-34	12.9	46
117	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 1713-1713	2.2	1
116	Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001. <i>Blood</i> , <b>2015</b> , 126, 248-248	2.2	5
115	Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 249-249	2.2	5
114	Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001. <i>Blood</i> , <b>2015</b> , 126, 251-251	2.2	2
113	Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia. <i>Blood</i> , <b>2015</b> , 126, 2597-2597	2.2	4
112	Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease. <i>Blood</i> , <b>2015</b> , 126, 2613-2613	2.2	4
111	Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , <b>2015</b> , 126, 306-306	2.2	2

110	Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy. <i>Blood</i> , <b>2015</b> , 126, 362-362	2.2	3
109	Expression of Sf3b1-K700E in Murine B Cells Causes Pre-mRNA Splicing and Altered B Cell Differentiation and Function. <i>Blood</i> , <b>2015</b> , 126, 366-366	2.2	1
108	Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 3765-3765	2.2	3
107	Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE). <i>Blood</i> , <b>2015</b> , 126, 543-543	2.2	8
106	A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. <i>Blood</i> , <b>2015</b> , 126, 80-80	2.2	24
105	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. <i>Blood</i> , <b>2015</b> , 126, 907-907	2.2	73
104	Comprehensive Bulk and Single Cell Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 2906-2906	2.2	1
103	The Impact of Insurance Status at Diagnosis on Overall Survival in Chronic Myeloid Leukemia: A Population-Based Analysis. <i>Blood</i> , <b>2015</b> , 126, 631-631	2.2	
102	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Blood</i> , <b>2015</b> , 126, 176-176	2.2	1
101	Comparison of Age at Diagnosis, Cytogenetic Risk, and Overall Survival Between Acute Myeloid Leukemia Patients of White and South Asian Race/Ethnicity in the United States. <i>Blood</i> , <b>2015</b> , 126, 3753-3753	2.2	2,2
100	Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2015</b> , 126, 3922-3922	2.2	
99	Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets. <i>Blood</i> , <b>2015</b> , 126, 2655-2655	2.2	
98	The End of Life for Patients with Acute Myeloid Leukemia (AML)- a Single Center Experience. <i>Blood</i> , <b>2015</b> , 126, 3318-3318	2.2	0
97	Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. <i>Blood</i> , <b>2015</b> , 126, 1304-1304	2.2	
96	The Impact of Age and Sex in DLBCL: Determination of Biologic Dynamics and Delineation of Inter-Connected Signaling Networks Via a Systems Biology Analysis. <i>Blood</i> , <b>2015</b> , 126, 2672-2672	2.2	
95	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. <i>Nature Communications</i> , <b>2014</b> , 5, 3469	17.4	140
94	Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. <i>Nature Genetics</i> , <b>2014</b> , 46, 618-23	36.3	84
93	Landscape of genomic alterations in cervical carcinomas. <i>Nature</i> , <b>2014</b> , 506, 371-5	50.4	541

92	Somatic mutation as a mechanism of Wnt/ $\beta$ -catenin pathway activation in CLL. <i>Blood</i> , <b>2014</b> , 124, 1089-98	2.2	56
91	Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1792-6	2.2	41
90	A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. <i>Leukemia Research</i> , <b>2014</b> , 38, 430-4	2.7	18
89	Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. <i>Blood</i> , <b>2014</b> , 123, 4101-10	2.2	55
88	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. <i>Blood</i> , <b>2014</b> , 124, 2705-12	2.2	411
87	Loss of function tp53 mutations do not accelerate the onset of myc-induced T-cell acute lymphoblastic leukaemia in the zebrafish. <i>British Journal of Haematology</i> , <b>2014</b> , 166, 84-90	4.5	12
86	Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. <i>Cancer Cell</i> , <b>2014</b> , 26, 813-825	24.3	216
85	Age-related clonal hematopoiesis associated with adverse outcomes. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 2488-98	59.2	2314
84	Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues. <i>Cancer Research</i> , <b>2014</b> , 74, 2796-802	10.1	34
83	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. <i>Blood</i> , <b>2014</b> , 124, 453-62	2.2	249
82	Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2691-8	2.2	295
81	NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. <i>Leukemia</i> , <b>2013</b> , 27, 2077-81	10.7	44
80	Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. <i>Cell</i> , <b>2013</b> , 152, 714-26	56.2	1006
79	Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). <i>British Journal of Haematology</i> , <b>2013</b> , 160, 530-7	4.5	97
78	Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1202-10	2.2	221
77	SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. <i>Cancer Cell</i> , <b>2013</b> , 23, 826-38	24.3	120
76	Reconstructing a Genotype-Phenotype Map In Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 2857-2857		1
75	Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial. <i>Blood</i> , <b>2013</b> , 122, 3062-3062		2

74	Clonal Evolution In Patients With Chronic Lymphocytic Leukemia (CLL) Developing Resistance To BTK Inhibition. <i>Blood</i> , <b>2013</b> , 122, 866-866	2.2	20
73	Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier. <i>Journal of Thrombosis and Haemostasis</i> , <b>2012</b> , 10, 1449-51	15.4	23
72	Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3791-802	12.9	69
71	Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. <i>Cell</i> , <b>2012</b> , 151, 344-55	56.2	243
70	Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. <i>Cancer Cell</i> , <b>2012</b> , 22, 359-72	24.3	148
69	Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. <i>Leukemia</i> , <b>2012</b> , 26, 2069-78	10.7	54
68	Comparison of Minimal Residual Disease Detection Using High-Throughput Sequencing and Allele-Specific Oligonucleotide PCR Methods in Pediatric B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2012</b> , 120, 2532-2532	2.2	1
67	Risk Alleles Identified in Genome-Wide Association Studies Are Associated with Expression Quantitative Trait Loci in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2012</b> , 120, 2875-2875	2.2	1
66	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. <i>Blood</i> , <b>2012</b> , 120, 311-311	2.2	1
65	Intensified Chemotherapy Regimen for Very High Risk Childhood B-Precursor Acute Lymphoblastic Leukemia (B-ALL): Results From Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 0501. <i>Blood</i> , <b>2012</b> , 120, 3563-3563	2.2	3
64	Somatic Mutation As a Mechanism of Wnt/ $\beta$ Catenin Pathway Activation in CLL. <i>Blood</i> , <b>2012</b> , 120, 559-559	2.2	2
63	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2012</b> , 120, 1470-1470	2.2	
62	Systematic Identification of Personal Mutated Tumor-Specific Neoantigens in CLL. <i>Blood</i> , <b>2012</b> , 120, 954-954	2.2	2
61	Association of Baseline Body Mass Index (BMI) with Overall Survival Among Patients Over Age 60 with Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2012</b> , 120, 1484-1484	2.2	
60	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2012</b> , 120, 1534-1534	2.2	
59	Galectin-1 Serum Levels Reflect Tumor Burden and Adverse Clinical Features in Hodgkin Lymphoma. <i>Blood</i> , <b>2012</b> , 120, 51-51	2.2	
58	Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS). <i>Blood</i> , <b>2012</b> , 120, 1700-1700	2.2	
57	SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 2497-506	59.2	875



56	The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 1373-9	7.5	90
55	Clinical effect of point mutations in myelodysplastic syndromes. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2496-506	59.2	1169
54	The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. <i>British Journal of Haematology</i> , <b>2011</b> , 152, 452-9	4.5	172
53	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , <b>2011</b> , 208, 1595-603	16.6	93
52	Shifts in Intra-Clonal Dynamics Rather Than Novel Mutations Are the Main Engine Driving Tumor Evolution in Relapsed CLL. <i>Blood</i> , <b>2011</b> , 118, 284-284	2.2	0
51	Obatoclox in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL. <i>Blood</i> , <b>2011</b> , 118, 2865-2865	2.2	1
50	Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium. <i>Blood</i> , <b>2011</b> , 118, 291-291	2.2	3
49	A Comparative Retrospective Survey of Reinduction Chemotherapy Regimens for Acute Myeloid Leukemia (AML) in First Relapse: A Single-Institution Experience. <i>Blood</i> , <b>2011</b> , 118, 4273-4273	2.2	1
48	Retrospective Analysis of Thrombocytopenia in Relapsed Multiple Myeloma Patients. <i>Blood</i> , <b>2011</b> , 118, 5073-5073	2.2	1
47	Randomized Comparison of IV PEG and IM E. Coli Asparaginase in Children and Adolescents with Acute Lymphoblastic Leukemia: Results of the DFCI ALL Consortium Protocol 05-01. <i>Blood</i> , <b>2011</b> , 118, 874-874	2.2	4
46	Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2011</b> , 118, 465-465	2.2	
45	Regadenoson, An Adenosine 2A Receptor Agonist, Is Safe and Inhibits Invariant NKT Cells in Sickle Cell Disease. <i>Blood</i> , <b>2011</b> , 118, 849-849	2.2	
44	Treatment of Chronic Lymphocytic Leukemia Patients with Lenalidomide Induces Down-Regulation of miR342-3p Associated with Over-Expression of Tumor Suppressor RASSF4,. <i>Blood</i> , <b>2011</b> , 118, 3885-3885	2.2	3,2
43	Large-Scale CLL Genome Analysis Reveals Novel Cancer Genes, Including SF3B1. <i>Blood</i> , <b>2011</b> , 118, 463-463	2.2	3
42	MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene. <i>Blood</i> , <b>2011</b> , 118, 2846-2846	2.2	
41	Rearrangement of 14q32 in the Absence of t(14;18) Is Associated with Short Time to First Treatment in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2011</b> , 118, 1438-1438	2.2	
40	Clinical Significance of Coagulation Studies in Predicting Response to Recombinant Factor VIIa in Cardiac Surgery Patients. <i>Blood</i> , <b>2011</b> , 118, 4351-4351	2.2	
39	Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. <i>Lancet Oncology</i> , <b>2010</b> , 11, 950-61	21.7	310

38	Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3816-23	2.2	79
37	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. <i>Blood</i> , <b>2010</b> , 116, 3268-77	2.2	903
36	T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. <i>Cancer Cell</i> , <b>2010</b> , 18, 353-66	24.3	121
35	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. <i>Blood</i> , <b>2009</b> , 114, 647-50	2.2	348
34	The Frequency and Management of Asparaginase-Related Thrombosis in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Treated On the Dana-Farber Cancer Institute (DFCI) Consortium Protocols.. <i>Blood</i> , <b>2009</b> , 114, 3073-3073	2.2	1
33	Dexamethasone and Individualized Asparaginase Dosing Are Each Associated with Superior Event-Free Survival in Childhood Acute Lymphoblastic Leukemia: Results From DFCI-ALL Consortium Protocol 00-01.. <i>Blood</i> , <b>2009</b> , 114, 321-321	2.2	11
32	MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 1285-90	11.5	202
31	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 3005-10	11.5	533
30	Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1106-11	2.2	101
29	Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. <i>Blood</i> , <b>2007</b> , 109, 896-904	2.2	319
28	Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. <i>Blood</i> , <b>2007</b> , 110, 1607-11	2.2	114
27	Large Regions of Uniparental Disomy (UPD) Establish Clonal Hematopoietic Stem Cell Selection in a Subset of Myelodysplastic Syndrome (MDS) Patients with Normal Bone Marrow Cell Karyotypes.. <i>Blood</i> , <b>2007</b> , 110, 120-120	2.2	2
26	A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.. <i>Blood</i> , <b>2007</b> , 110, 1358-1358	2.2	2
25	Increased Risk of Skeletal Toxicity and Infection in Children 10 Years or Older Treated for Acute Lymphoblastic Leukemia (ALL) with Dexamethasone: Results from the DFCI ALL Consortium.. <i>Blood</i> , <b>2007</b> , 110, 849-849	2.2	1
24	Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.. <i>Blood</i> , <b>2007</b> , 110, 2331-2331	2.2	
23	Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukemias.. <i>Blood</i> , <b>2006</b> , 108, 1405-1405	2.2	2
22	Engineered Expression of JAK2V617F Drastically Changes the Response of Progenitor Cells to Erythropoietin and Partially Mimics the Polycythemia Expression Signature.. <i>Blood</i> , <b>2006</b> , 108, 3597-3597	2.2	2
21	Intravenous PEG Asparaginase during Remission Induction for Childhood ALL.. <i>Blood</i> , <b>2006</b> , 108, 1854-1854		1

20	Bcl2 Accelerates Onset but Not Progression of MYC-Induced T-Cell Leukemia in Transgenic Zebrafish.. <i>Blood</i> , <b>2006</b> , 108, 1829-1829	2.2	
19	Pharmacodynamics and Tolerability of Twice-Weekly Erwinia Asparaginase after E. coli Asparaginase Allergy in Children with ALL.. <i>Blood</i> , <b>2006</b> , 108, 1857-1857	2.2	1
18	Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.. <i>Blood</i> , <b>2006</b> , 108, 3041-3041	2.2	
17	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. <i>Blood</i> , <b>2005</b> , 105, 1851-61	2.2	654
16	Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 1797-805	15.9	221
15	HOXB9 Is Aberrantly Expressed in Blast Cells in a Subset of Acute Myeloid Leukemia Patients and Supports Proliferation of AML Cell Lines. <i>Blood</i> , <b>2005</b> , 106, 1613-1613	2.2	1
14	Addition of Bortezomib (Velcade) to AML Induction Chemotherapy Is Well Tolerated and Results in a High Complete Remission Rate.. <i>Blood</i> , <b>2005</b> , 106, 2782-2782	2.2	3
13	Expression of T Cell Co-Stimulator (ICOS) and Its Ligand and Disease Progression in B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , <b>2005</b> , 106, 2943-2943	2.2	1
12	Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. <i>Cancer Cell</i> , <b>2002</b> , 1, 75-87	24.3	895
11	Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin@ lymphoma. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 3128-35	2.2	159
10	Using recursive partitioning for exploration and follow-up of linkage and association analyses. <i>Genetic Epidemiology</i> , <b>1999</b> , 17 Suppl 1, S391-6	2.6	6
9	Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant. <i>Blood</i> , <b>1998</b> , 91, 3671-3680	2.2	273
8	Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. <i>Blood</i> , <b>1998</b> , 91, 3671-80	2.2	51
7	Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. <i>Journal of Clinical Investigation</i> , <b>1997</b> , 100, 855-66	15.9	75
6	Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. <i>Blood</i> , <b>1994</b> , 84, 3974-3979	2.2	47
5	Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. <i>Blood</i> , <b>1993</b> , 81, 3449-3457	2.2	284
4	Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. <i>Blood</i> , <b>1993</b> , 81, 3449-3457	2.2	6
3	A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation		2

2	Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes	2
1	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias	1